Affymetrix last week ended months of speculation about whether and how it would compete in the gene-sequencing market by disclosing plans for a new technology that combines microarrays to capture regions of the genome with on-chip enzymatic sequencing.

Get the full story with GenomeWeb Premium

Only $95 for the first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

In this webinar, the first in the “New Frontiers in Liquid Biopsy Research” series, Bea Bellosillo, head of pathology at the Hospital del Mar, will discuss her experience evaluating an early-access lung cancer panel that detects copy number variants and fusions.